Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices

Journal of Bone and Mineral Research

Volumn 14, Issue 5, 1999, Pages 792-801

  Woitge, Henning W ^a   Pecherstorfer, Martin ^b   Li, Yuming ^a   Keck, Andrea V ^b   Horn, Eva ^b   Ziegler, Reinhard ^a   Seibel, Markus J ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Medicine ^*  (Austria)

^c Div of Endocrinology and Metabolism   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; SIALOPROTEIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE METABOLISM; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIMARY HYPERPARATHYROIDISM; RISK ASSESSMENT; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DISEASES; BONE NEOPLASMS; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PEPTIDES; RADIOIMMUNOASSAY; SIALOGLYCOPROTEINS;

EID: 0032952132     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.5.792     Document Type: Article

References (33)

1. Calvo MS, Eyre DR, Gundberg CM 1996 Molecular basis and clinical application of biological markers of bone turnover. Endoer Rev 17:333-368.
2. Seibel MJ, Robins SP, Bilezikian JP 1992 Urinary pyridinium crosslinks of collagen: Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 3:263-270.
3. Hanson D, Weis M, Bollen A-M, Maslan S, Singer F, Eyre D 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1257.
4. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Evaluation of an immunoassay for quantitation of type I collagen degradation products in urine. Clin Chem 40:2022-2025.
5. Hannon RA, Blumsohn A, Naylor K, Eastell R 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 13:1124-1133.
6. Risteli J, Elonaa I, Niemi S, Novamo A, Risteli L 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 39:635-640.
7. Hassager C, Jensen LT, Pødenphant J, Thomsen K, Christiansen C 1994 The carboxy-terminal pyridinoline crosslinked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 54:30-33.
8. Bonde M, Garnero P, Fledelius C, Quist P, Delmas PD, Christiansen C 1997 Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12:1028-1034.
9. Clemens JD, Herrick MV, Singer FR, Eyre DR 1997 Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058-2063.
10. Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, Armbruster FP 1997 Improved purification of bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem 43:2076-2082.
11. Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R 1996 Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81:3289-3294.
12. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, Cheresh DA 1993 Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 268:9901-9907.
13. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N 1994 The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141.
14. Durie BGM, Salmon SE 1975 A clinical staging system for multiple myeloma. Cancer 36:842-854.
15. Woitge HW, Seibel MJ, Ziegler R 1996 Comparison of total and bone-specific alkaline phosphatase in patients with non-skeletal disorder or metabolic bone diseases. Clin Chem 42:1796-1804.
16. Pratt DA, Daniloff Y, Duncan A, Robins SP 1992 Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem 207:168-175.
17. Helger R, Rindfrey H, Hilgenfeldt J 1974 Eine Methode zur direkten Bestimmung des Creatinins im Serum und Urin ohne Enteiweissung nach einer spezifischen modifizierten Jaffé-Reaktion. Z Klin Chem Klin Biochem 12:344-349.
18. Robins SP, Woitge HW, Hesley R, Ju J, Seyedin S, Seibel MJ 1994 Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649.
19. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP 1994 Urinary hydroxypyridinium crosslinks of collagen in a population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 9:1433-1440.
20. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG 1993 Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 3:255-260.
21. Seibel MJ, Cosman F, Shen V, Ratcliffe A, Lindsay R 1993 Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8:881-889.
22. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
23. Christiansen C, Riis BJ, Rodboro P 1987 Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105-1108.
24. Van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, Birkenhager JC, Pols HAP 1996 Case control analysis of bone resorption markers, disability and hip fracture risk: The Rotterdam study. BMJ 312:482-483.
25. Seibel MJ, Gartenberg F, Ratcliffe A, Robins SP, Silberberg J, Bilezikian JP 1992 Urinary hydroxy-pyridinium crosslinks of collagen as specific indices of bone resorption in primary hyperparathyroidism. J Clin Endocrinol Metab 74:481-486.
26. Papapoulos SE 1997 Paget's disease of bone: Clinical, pathogenetic and therapeutic aspects. Baillieres Clin Endocrinol Metab 11:117-143.
27. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Köhn H, Bayer P, Thiebaud D, Ludwig H 1997 Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridnium crosslinks of collagen. Blood 9:3743-3750.
28. Fleisch H 1994 Bisphosphonates: Pharmacology. Semin Arthritis Rheum 23:261-262.
29. Pedrazzoni M, Alfano FS, Gatti C, Fantuzzi M, Girasole G, Campanini C, Basini G, Passeri M 1995 Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 57:25-29.
30. Blumsohn A, Navlor KE, Assiri AMA, Eastell R 1995 Different responses on biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 41:1592-1598.
31. Gundberg CM, Clough ME 1992 The osteocalcin propeptide is not secreted in vivo or in vitro. J Bone Miner Res 7:73-80.
32. McLaren AM, Isdale AH, Whiting PH, Bird HA, Robins SP 1993 Physiological variations in the urinary excretion of pyridinium crosslinks of collagen. Br J Rheumatol 32:307-312.
33. Guañabens N, Parés A, Alvarez L, Martínez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodès J 1998 Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 13:731-738.